Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maxicold (often misspelled as Maxicom in some contexts) is a multi-component over-the-counter (OTC) medication developed and marketed by OTCPharm for the symptomatic relief of the common cold, influenza, and other acute respiratory viral infections (ARVI). The standard formulation is typically a powder for oral solution containing paracetamol (analgesic and antipyretic), phenylephrine hydrochloride (nasal decongestant), pheniramine maleate (antihistamine), and ascorbic acid (Vitamin C). Paracetamol reduces fever and pain by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine acts as an alpha-1 adrenergic receptor agonist to reduce nasal mucosal edema and congestion. Pheniramine is an H1-receptor antagonist that alleviates allergic-like symptoms such as sneezing and rhinorrhea. Ascorbic acid is included to support immune function during infection. The brand also encompasses other formulations, including throat sprays and pediatric suspensions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Maxicold.